These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Carboplatin (CBDCA)-hexamethylmelamine (HMM)-oral etoposide (VP-16) first-line treatment of ovarian cancer patients with bulky disease: a phase II study. Frasci G; Comella G; Comella P; Conforti S; Mastrantonio P; Zullo F; Persico G Gynecol Oncol; 1995 Jul; 58(1):68-73. PubMed ID: 7789893 [TBL] [Abstract][Full Text] [Related]
6. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens. Muggia FM; Groshen S; Russell C; Jeffers S; Chen SC; Schlaerth J; Curtin J; Morrow CP Gynecol Oncol; 1993 Aug; 50(2):232-8. PubMed ID: 8375739 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of ifosfamide and cisplatinum in advanced ovarian cancer. Aziz Z; Zahid M; Ud Din Ahmed Z; Arshad T Aust N Z J Med; 1998 Jun; 28(3):403-9. PubMed ID: 9673759 [TBL] [Abstract][Full Text] [Related]
8. Combination therapy with carboplatin/cisplatin/ifosfamide/etoposide in ovarian cancer. Lund B; Hansen OP; Hansen HH; Hansen M Semin Oncol; 1992 Feb; 19(1 Suppl 1):26-9. PubMed ID: 1411618 [TBL] [Abstract][Full Text] [Related]
9. Carboplatin, etoposide, and ifosfamide as second-line treatment for ovarian cancer. Fanning J; Hilgers RD; Hutson E Am J Clin Oncol; 1994 Aug; 17(4):335-7. PubMed ID: 8048396 [TBL] [Abstract][Full Text] [Related]
10. Etoposide and carboplatin as salvage and first-line therapy in ovarian cancer patients. Dittrich C; Baur M; Vavra N; Hudec M; Fazeny B; Barrada M; Salzer H; Sevelda P Ann Oncol; 1993 Sep; 4(8):697-9. PubMed ID: 8241004 [TBL] [Abstract][Full Text] [Related]
11. Phase II trial of etoposide, carboplatin, and ifosfamide as salvage therapy in advanced ovarian carcinoma. Beddoe AM; Dottino PR; Cohen CJ Mt Sinai J Med; 1993 Sep; 60(4):311-6. PubMed ID: 8232377 [TBL] [Abstract][Full Text] [Related]
12. A phase I trial of intraperitoneal carboplatin and etoposide with granulocyte macrophage colony stimulating factor support in patients with intraabdominal malignancies. McClay EF; Braly PD; Kirmani S; Plaxe SC; McClay ME; Wilgus L; Kim S; Howell SB Cancer; 1994 Jul; 74(2):664-9. PubMed ID: 8033046 [TBL] [Abstract][Full Text] [Related]
13. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer. Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477 [TBL] [Abstract][Full Text] [Related]
14. High dose chemotherapy with ifosfamide, carboplatin, and etoposide combined with autologous bone marrow transplantation for the treatment of poor-prognosis germ cell tumors and metastatic trophoblastic disease in adults. Lotz JP; André T; Donsimoni R; Firmin C; Bouleuc C; Bonnak H; Merad Z; Esteso A; Gerota J; Izrael V Cancer; 1995 Feb; 75(3):874-85. PubMed ID: 7828139 [TBL] [Abstract][Full Text] [Related]
15. Salvage intraperitoneal therapy of ovarian cancer employing cisplatin and etoposide: a Gynecologic Oncology Group study. Markman M; Blessing JA; Major F; Manetta A Gynecol Oncol; 1993 Aug; 50(2):191-5. PubMed ID: 8375734 [TBL] [Abstract][Full Text] [Related]
16. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. Reichman B; Markman M; Hakes T; Hoskins W; Rubin S; Jones W; Almadrones L; Ochoa M; Chapman D; Saigo P J Clin Oncol; 1989 Sep; 7(9):1327-32. PubMed ID: 2671288 [TBL] [Abstract][Full Text] [Related]
17. A phase I-II study of high-dose melphalan, mitoxantrone and carboplatin with peripheral blood stem cell support in patients with advanced ovarian or breast carcinoma. Weaver CH; Greco FA; Hainsworth JD; Zhen B; Baldwin P; Wittlin F; Lewis M; West WH; Schwartzberg L; Buckner CD Bone Marrow Transplant; 1997 Nov; 20(10):847-53. PubMed ID: 9404925 [TBL] [Abstract][Full Text] [Related]
18. Phase II trial of intraperitoneal carboplatin in ovarian carcinoma patients with macroscopic residual disease at second-look laparotomy. A multicentre study of the French Fédération Nationale des Centres de Lutte Contre le Cancer. Guastalla JP; Lhomme C; Kerbrat P; Mayer F; Namer M; Goupil P; Charrot P; Heron JF; Chazard M; Richard I Ann Oncol; 1994 Feb; 5(2):127-32. PubMed ID: 8186155 [TBL] [Abstract][Full Text] [Related]
19. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors. Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380 [TBL] [Abstract][Full Text] [Related]
20. Carboplatin/etoposide as first-line chemotherapy in advanced ovarian carcinoma: a pilot study. Eiermann W; Achterrath W; Lenaz L; Hepp H Cancer Chemother Pharmacol; 1991; 27(5):389-93. PubMed ID: 1998999 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]